Skip to content

Visionary Ventures

Life sciences venture capital fund investing in ophthalmology and medical aesthetics.

HOME
OPHTHALMOLOGY FUND
Visionary KOLs
TEAM
- Investment Committee
- Fund Management
PORTFOLIO
NEWS
CONTACT
INVESTOR LOGIN

Fund Menu

Search:

HOME
OPHTHALMOLOGY FUND
Visionary KOLs
TEAM
- Investment Committee
- Fund Management
PORTFOLIO
NEWS
CONTACT
INVESTOR LOGIN

Dr. Bob Avery

International lecturer on retinal diseases. Founder of the California Retina Research Foundation

Search:

Recent Posts

Orasis Pharmaceuticals Announces Novel Corrective Eyedrop for Presbyopia, Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, Now Available to Prescribe in the U.S.
April 7, 2025
Sydnexis Announces Positive CHMP Opinion in Europe for SYD-101 for Slowing the Progression of Pediatric Myopia
April 1, 2025
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
March 26, 2025

Categories

Acquisition(2)
Aurion(6)
IanTECH(2)
Iantrek(2)
IPO(2)
License Deal(1)
News(74)
ONL(3)
Orasis(18)
Pelage(2)
Re-Vana(4)
RxSight(2)
Surface(1)
Sydnexis(6)
Tarsus(7)
Tear Film(4)
TearClear(8)
Visionary(9)

Archives

Visionary Ventures

Visionary Ventures is a venture capital fund that invests in life sciences and the future of ophthalmology and medical aesthetics. We are an opportunistic venture fund that invests in early and late stages of a company's growth, from early-stage Series A rounds in clinical trials to late-stage rounds in commercialization. Our target investment range is $5M to $15M.

Contact Us

Visionary Ventures
620 Newport Center Drive, Suite 650
Newport Beach CA 92660
info@visionaryvc.com

Home
Ophthalmology
Team
Portfolio
News
Contact
Investor Portal

Footer Menu

© 2019 Visionary Ventures. All Rights Reserved.